Aldeyra Therapeutics Has Data To Trigger AbbVie Partnership [Seeking Alpha]
Aldeyra Therapeutics, Inc. (ALDX)
Last aldeyra therapeutics, inc. earnings: 11/7 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.aldeyra.com/investor-relations
Company Research
Source: Seeking Alpha
2.08K Follower s Follow Summary Aldeyra Therapeutics' Reproxalap eye drop for Dry Eye Disease has new positive data for the second NDA attempt. Aldeyra has an option agreement with AbbVie, potentially leading to significant milestone payments and a 60%/40% partnership if FDA approval is granted. Reproxalap offers immediate and long-term relief, a significant advantage over existing therapies like Xiidra and Restasis, enhancing its market potential. Aldeyra has $120 million in cash and a market cap of about $319 million. choja On August 8 th , Aldeyra Therapeutics, Inc. ( NASDAQ: ALDX seemingly achieved its final clinical step in its long and winding road to achieve FDA approval for its Dry Eye Disease (DED) eye drop, called Reproxalap . Approval, if granted, should trigger the exercise of an exclusive option owned by AbbVie Inc. ( ABBV ) that would result in significant milestone payments and the creation of a 60%/40% partnership (with Aldeyra being the minority owner
Show less
Read more
Impact Snapshot
Event Time:
ALDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALDX alerts
High impacting Aldeyra Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALDX
News
- Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 MeetingBusiness Wire
- Aldeyra Therapeutics resubmits new drug application for treatment of dry eye disease [Seeking Alpha]Seeking Alpha
- Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye DiseaseBusiness Wire
- Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceBusiness Wire
- Aldeyra Therapeutics Inc (NASDAQ:ALDX) A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
ALDX
Earnings
- 11/7/24 - In-Line
ALDX
Sec Filings
- 11/7/24 - Form 10-Q
- 10/21/24 - Form 4
- 10/3/24 - Form 8-K
- ALDX's page on the SEC website